Schizotypal Personality Disorder
11
0
0
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
18.2%
2 terminated out of 11 trials
75.0%
-11.5% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Evolutionary Systems Therapy for Schizotypy
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
Compassion and Metacognition in Schizotypal Personality
Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample
A D1 Agonist For Working Memory
Schizotypal Personality Disorder Risperidone
CRT-Guanfacine for SPD
Pharmacology of Cognition in Schizotypal Personality Disorder
Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder
Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder